Physician profile
Lance W Hall
NPI 1992886923
$517.52
in general payments reported to CMS, 2019-2025
11 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.65 · 2023: $71.63 · 2024: $259 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $105.87 | 2022-2025 | Mounjaro, Zepbound |
| Noven Therapeutics, LLC | $89.43 | 2023-2025 | Secuado, Xelstrym |
| Antares Pharma, INC. | $86.26 | 2024-2025 | Xyosted |
| Novo Nordisk INC | $65.67 | 2022-2025 | Wegovy |
| Tris Pharma INC | $45.86 | 2024 | Dyanavel Xr |
| Amgen INC. | $38.53 | 2023-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $20.14 | 2024 | |
| Exact Sciences Corporation | $18.50 | 2024 | Cologuard Collection Kit |
| Linus Health, INC. | $16.08 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2022 | |
| Insulet Corporation | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.